Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate (HypoFX)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01868386 |
Recruitment Status :
Completed
First Posted : June 4, 2013
Last Update Posted : April 28, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Radiation therapy is one of the standard treatments for men with prostate cancer who have detectable levels of prostate specific antigen (PSA, a prostate cancer specific marker) after surgery. When radiation therapy is given to patients who have an increase in PSA after surgery, it is called "salvage radiation therapy". Currently the standard radiation therapy course length for this type of cancer is around 7 ½ -8 weeks. Sometimes, radiation therapy after prostate removal causes unpleasant side effects. A shorter course of radiation therapy, known as a "hypofractionated" course, gives fewer but higher doses of radiation than standard radiation.
The purpose of this study is to test the safety of a shorter course of radiation therapy at progressively lower dose levels and shorter lengths of treatment (hypofractionated) with patients who have had their prostate removed. The study will assess whether the hypofractionated course works better without causing additional side effects to the remaining cancer cells in the prostate bed.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer | Radiation: Hypofractionated therapy | Phase 1 Phase 2 |
Primary Objectives:
To determine the shortest dose-fractionation schedule (Dose Schedule) with acceptable grade ¡Ã 3 GU/GI toxicity rate for salvage HypoFx RT to maintain a constant, high BED for prostate cancer response while reducing the BED for late GU and GI toxicity
To assess health-related quality of life (HRQOL) of the recommended Dose Schedule of salvage HypoFx RT by demonstrating no significant change in 1-year disease specific QoL, as compared to baseline
Secondary Objectives:
To evaluate and characterize the acute and late genitourinary (GU) and gastrointestinal (GI) adverse effects associated with postoperative, hypofractionated radiation therapy.
To evaluate biochemical failure rate, defined separately as nadir plus 2 ng/mL and as three consecutive rises in PSA, at 2 years after hypofractionated, post-prostatectomy radiation therapy.
To evaluate health utilities at 1 year after HypoFx salvage RT, as measured by the EQ-5D instrument.
To evaluate changes in sexual domain of EPIC quality of life instrument at 1 year after HypoFx salvage RT.
To evaluate the treatment burden for patients undergoing salvage HypoFx RT, in order to examine whether HypoFx RT results in less burdensome treatment for patients, as measured by patient-reported direct and indirect (i.e., transportation) health care costs and lost productivity due to treatment, as evaluated by the Work Productivity and Activity Impairment Questionnaire¢-General Health (WPAI-GH).
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Hypofractionated Post-prostatectomy Radiotherapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase I/II Trial |
Study Start Date : | April 2013 |
Actual Primary Completion Date : | December 2020 |
Actual Study Completion Date : | December 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Dose Level 1
Hypofractionated therapy, 26 treatments at 2.5 Gy
|
Radiation: Hypofractionated therapy
Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm |
Experimental: Dose Level 2
Hypofractionated therapy, 20 treatments at 2.83Gy
|
Radiation: Hypofractionated therapy
Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm |
Experimental: Dose Level 3
Hypofractionated therapy,15 treatments at 3.36 Gy
|
Radiation: Hypofractionated therapy
Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm |
Experimental: Dose Level 4
Hypofractionated therapy, 10 treatments at 4.26 Gy
|
Radiation: Hypofractionated therapy
Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm |
- Dose limiting toxicity [ Time Frame: over a period of 2 years ]Incidence of GU (genitourinary) and GI (gastrointestinal) toxicities of CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or greater
- Quality of life measure [ Time Frame: over a period of 2 years ]To compare quality of life post-procedure from baseline
- Biochemical failure rate [ Time Frame: over a period of 2 years ]A biochemical failure is defined as an increase in prostate serum antigen concentration to nadir plus 2ng/mL or 3 consecutive increases in PSA
- Acute and late GU and GI toxicity [ Time Frame: over a period of two years ]
- Health Utilities [ Time Frame: 1 year after radiation treatment ]
- EPIC Prostate Cancer-Specific QOL instrument [ Time Frame: over a period of two years ]looking at changes in sexual and hormonal domains
- Ancillary financial burden [ Time Frame: over a period of two years ]estimating out-of-pocket costs and lost wages for patients during treatment

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosis of prostate adenocarcinoma and
- have had a prostatectomy
- have detectable PSA
- 18 years of age or older
Exclusion Criteria:
- are receiving chemotherapy or other agents intended for cancer treatment
- history of rectal surgery or lower gastrointestinal bleed
- history of bleeding diathesis or abnormal sensitivity to ionizing radiation
- had prior pelvic irradiation or are scheduled to receive pelvic nodal irradiation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01868386
United States, Virginia | |
University of Virginia Health System | |
Charlottesville, Virginia, United States, 22908 | |
Southwest Virginia Regional Cancer Center | |
Norton, Virginia, United States, 24273 | |
Virginia Commonwealth University | |
Richmond, Virginia, United States, 23220 |
Principal Investigator: | Timothy Showalter, MD | University of Virginia School of Medicine |
Responsible Party: | Timothy Showalter, MD, Professor, Radiation Oncology, University of Virginia |
ClinicalTrials.gov Identifier: | NCT01868386 |
Other Study ID Numbers: |
16604 |
First Posted: | June 4, 2013 Key Record Dates |
Last Update Posted: | April 28, 2021 |
Last Verified: | April 2021 |
Radiotherapy, hypofractionated Salvage therapy Radiotherapy, adjuvant |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |